Completion of Rights Issue
Released
Released
Announcement PDF
WHERE
BIOTECHNOLOGY
&
N A N O T E C H N O L OG Y
MEET
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
19 October 2018
Completion of Rights Issue
Imagion Biosystems Limited (the Company) advises that the 1-for-2 pro-rata non-renounceable rights issue
at an issue price of $0.04 (Offer) as announced by the Company on 20 September 2018 closed on
Wednesday 17 October 2018, with the following results (which remain subject to cheque clearances):
Maximum New Shares available under the Offer
107,147,608 Shares
Number of New Entitlement Shares applied for under the Offer
8,356,748 Shares
Number of New Additional Shares applied for under the Offer
1,916,350 Shares
Total New Shares applied for under the Offer
10,273,098 Shares
Issue price per Share under Offer
$0.04
Total Application funds received under Offer
$410,924
Number of Shortall Shares
96,874,510 Shares
The Company will issue and allot the New Shares applied for under the Offer on 24 October 2018. The New
Shares issued under the Offer will be fully paid and will rank equally with the Company’s existing Shares.
The Company will make an application to the ASX for official quotation of the New Shares.
The Directors reserve the right to place any or all of the remaining Shortfall Shares at the Offer price at their
discretion to sophisticated and/or professional investors (under section 708 of the Corporations Act 2001
(Cth) (the Act)) within 3 months of the close of the Offer (Shortfall Placement).
The Shortfall Placement will be managed by the Lead Manager to the Offer, Pamplona Corporate Pty Ltd,
pursuant to a mandate agreement. Under the key terms of the mandate agreement (which are set out in the
Offer Document), the Lead Manager was entitled to receive a management fee of $25,000, and a selling fee
of 6.0% of the funds raised under the Shortfall Placement (Selling Fee). Subsequent to the date of the Offer
Document, the Lead Manager and the Company have agreed that the Selling Fee may be paid in cash or
equity, or a combination of them. In particular, the Selling Fee may be paid by the Company as follows:
▪
▪
▪
by payment of cash equal to 6.0% of the funds raised under the Shortfall Placement (Cash Fee); or
by the issue of Options exercisable at $0.06, expiring 24 months after date of issue, on the basis of
0.4 Options per 1 Share subscribed under the Shortfall Placement (Option Fee); or
a combination of the Cash Fee and the Option Fee.
The Selling Fee includes all fees payable to other brokers by the Lead Manager under the Shortfall
Placement.
-ENDS
For further information please visit www.imagionbiosystems.com
U.S. Media Contact:
Australian Media & Investor Relations:
Matthew Wygant
Matt Wright, NWR Communications
matthew@biotechwriting.com
matt@nwrcommunications.com.au
+1-408-905-7630
+61-451-896-420
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
Share your feedback
Discover